Affibody Announces Option Exercise by Daewoong

Solna, Sweden, April 30, 2020. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced that its partner Daewoong, a South Korea-based pharmaceutical company, has exercised an option under the companies’ ongoing collaboration.
Läs mer